Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Opportunities for improving therapy development in ALS.

Bruijn L, Cudkowicz M; ALS Clinical Trials Working Group.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):169-73. doi: 10.3109/21678421.2013.872662. Epub 2014 Jan 29.

PMID:
24472060
2.

Toward more efficient clinical trials for amyotrophic lateral sclerosis.

Cudkowicz ME, Katz J, Moore DH, O'Neill G, Glass JD, Mitsumoto H, Appel S, Ravina B, Kieburtz K, Shoulson I, Kaufmann P, Khan J, Simpson E, Shefner J, Levin B, Cwik V, Schoenfeld D, Aggarwal S, McDermott MP, Miller RG.

Amyotroph Lateral Scler. 2010 May 3;11(3):259-65. doi: 10.3109/17482960903358865. Review.

PMID:
19961263
3.

Design of phase II ALS clinical trials.

Schoenfeld DA, Cudkowicz M.

Amyotroph Lateral Scler. 2008;9(1):16-23. doi: 10.1080/17482960701875896.

PMID:
18273715
4.

Predicting success: optimizing phase II ALS trials for the transition to phase III.

Berry JD, Cudkowicz ME, Shefner JM.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Mar;15(1-2):1-8. doi: 10.3109/21678421.2013.838969. Review.

PMID:
24588460
5.

Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs.

Goyal NA, Mozaffar T.

Expert Opin Investig Drugs. 2014 Nov;23(11):1541-51. doi: 10.1517/13543784.2014.933807. Epub 2014 Jun 26. Review.

PMID:
24965719
6.

Infrastructure resources for clinical research in amyotrophic lateral sclerosis.

Sherman AV, Gubitz AK, Al-Chalabi A, Bedlack R, Berry J, Conwit R, Harris BT, Horton DK, Kaufmann P, Leitner ML, Miller R, Shefner J, Vonsattel JP, Mitsumoto H.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14 Suppl 1:53-61. doi: 10.3109/21678421.2013.779058. Review.

PMID:
23678880
7.

An efficient multi-stage, single-arm Phase II futility design for ALS.

Palesch YY, Tilley BC.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:55-6. No abstract available.

PMID:
15512874
8.

Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?

Nicholson KA, Cudkowicz ME, Berry JD.

Neurotherapeutics. 2015 Apr;12(2):376-83. doi: 10.1007/s13311-015-0341-2. Review.

9.

Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial.

Leigh PN, Swash M, Iwasaki Y, Ludolph A, Meininger V, Miller RG, Mitsumoto H, Shaw P, Tashiro K, Van Den Berg L.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Jun;5(2):84-98. Review.

PMID:
15204010
10.

Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?

Mitsumoto H, Brooks BR, Silani V.

Lancet Neurol. 2014 Nov;13(11):1127-38. doi: 10.1016/S1474-4422(14)70129-2. Review.

PMID:
25316019
11.

The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials.

Berry JD, Miller R, Moore DH, Cudkowicz ME, van den Berg LH, Kerr DA, Dong Y, Ingersoll EW, Archibald D.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 Apr;14(3):162-8. doi: 10.3109/21678421.2012.762930. Epub 2013 Jan 17. Review.

PMID:
23323713
12.

New therapy options for amyotrophic lateral sclerosis.

Gordon P, Corcia P, Meininger V.

Expert Opin Pharmacother. 2013 Oct;14(14):1907-17. doi: 10.1517/14656566.2013.819344. Epub 2013 Jul 16. Review.

PMID:
23855817
13.

[Update on fundamental and clinical research in amyotrophic lateral sclerosis].

Pradat PF, Camdessanché JP, Carluer L, Cintas P, Corcia P, Danel-Brunaud V, Echaniz-Laguna A, Gonzalez J, Nicolas G, Vandenberghe N, Verschueren A; coordination des centres de prise en charge des patients atteints de SLA.

Rev Neurol (Paris). 2009 Jun-Jul;165(6-7):532-41. doi: 10.1016/j.neurol.2009.01.038. Epub 2009 May 5. Review. French.

PMID:
19419744
14.

Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?

Zach N, Ennist DL, Taylor AA, Alon H, Sherman A, Kueffner R, Walker J, Sinani E, Katsovskiy I, Cudkowicz M, Leitner ML.

Neurotherapeutics. 2015 Apr;12(2):417-23. doi: 10.1007/s13311-015-0336-z. Review.

15.

Use of biomarkers in ALS drug development and clinical trials.

Bakkar N, Boehringer A, Bowser R.

Brain Res. 2015 May 14;1607:94-107. doi: 10.1016/j.brainres.2014.10.031. Epub 2014 Oct 24. Review.

16.

ALS biomarkers for therapy development: State of the field and future directions.

Benatar M, Boylan K, Jeromin A, Rutkove SB, Berry J, Atassi N, Bruijn L.

Muscle Nerve. 2016 Feb;53(2):169-82. doi: 10.1002/mus.24979. Epub 2015 Dec 29. Review.

17.

Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology.

Ince PG, Lowe J, Shaw PJ.

Neuropathol Appl Neurobiol. 1998 Apr;24(2):104-17. Review.

PMID:
9634206
18.

Translating biological findings into new treatment strategies for amyotrophic lateral sclerosis (ALS).

Poppe L, Rué L, Robberecht W, Van Den Bosch L.

Exp Neurol. 2014 Dec;262 Pt B:138-51. doi: 10.1016/j.expneurol.2014.07.001. Epub 2014 Jul 11. Review.

19.

Proposed BioRepository platform solution for the ALS research community.

Sherman A, Bowser R, Grasso D, Power B, Milligan C, Jaffa M, Cudkowicz M.

Amyotroph Lateral Scler. 2011 Jan;12(1):11-6. doi: 10.3109/17482968.2010.539233. Epub 2010 Dec 6.

PMID:
21128868
20.

New therapeutic targets for amyotrophic lateral sclerosis.

Kuzma-Kozakiewicz M, Kwiecinski H.

Expert Opin Ther Targets. 2011 Feb;15(2):127-43. doi: 10.1517/14728222.2011.542152. Epub 2010 Dec 7. Review.

PMID:
21133819

Supplemental Content

Support Center